Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial - Moliterno, DJ; Califf, RM; Aguirre, FV; Anderson, K; Sigmon, KN; Weisman, HF (Am J Cardiol, 1995)